Alnylam Pharmaceuticals, Inc. (ALNY)
Largest Insider Buys in Sector
ALNY Stock Price History Chart
ALNY Stock Performance
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Alnylam Pharmaceuticals, Inc.
Over the last 12 months, insiders at Alnylam Pharmaceuticals, Inc. have bought $0 and sold $49M worth of Alnylam Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Alnylam Pharmaceuticals, Inc. have bought $0 and sold $44.8M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 595,002 shares for transaction amount of $42.76M was made by Sanofi (10 percent owner) on 2017‑05‑31.
List of Insider Buy and Sell Transactions, Alnylam Pharmaceuticals, Inc.
| 2024-12-12 | Sale | CMO & EVP Dev & Med Affairs | 1,752 0.0014% | $251.00 | $439,760 | -1.58% | ||
| 2024-11-27 | Sale | CSO & EVP, Head of Research | 1,531 0.0012% | $252.29 | $386,261 | -3.27% | ||
| 2024-11-26 | Sale | Chief Executive Officer | 5,219 0.004% | $250.98 | $1.31M | -3.12% | ||
| 2024-11-26 | Sale | EVP, Chief Financial Officer | 1,682 0.0013% | $250.98 | $422,144 | -3.12% | ||
| 2024-11-26 | Sale | CMO & EVP Dev & Med Affairs | 1,682 0.0013% | $250.98 | $422,144 | -3.12% | ||
| 2024-11-26 | Sale | CSO & EVP, Head of Research | 1,469 0.0011% | $250.98 | $368,686 | -3.12% | ||
| 2024-11-26 | Sale | EVP, Chief Commercial Officer | 1,469 0.0011% | $250.98 | $368,686 | -3.12% | ||
| 2024-08-20 | Sale | Chief Executive Officer | 15,000 0.0117% | $280.00 | $4.2M | -5.76% | ||
| 2024-08-12 | Sale | CSO & EVP, Head of Research | 22,025 0.0172% | $270.99 | $5.97M | -1.82% | ||
| 2024-08-06 | Sale | director | 20,250 0.0157% | $262.00 | $5.31M | +1.53% | ||
| 2024-08-01 | Sale | Chief Executive Officer | 15,148 0.012% | $270.00 | $4.09M | -1.00% | ||
| 2024-07-11 | Sale | Chief Executive Officer | 7,093 0.006% | $261.00 | $1.85M | 0.00% | ||
| 2024-06-25 | Sale | Chief Executive Officer | 8,301 0.0063% | $230.99 | $1.92M | +9.36% | ||
| 2024-06-25 | Sale | EVP, Chief Financial Officer | 1,605 0.0012% | $231.00 | $370,747 | +9.36% | ||
| 2024-06-25 | Sale | CMO & EVP Dev & Med Affairs | 2,103 0.0016% | $230.99 | $485,773 | +9.36% | ||
| 2024-06-25 | Sale | CSO & EVP, Head of Research | 1,198 0.0009% | $230.99 | $276,731 | +9.36% | ||
| 2024-06-25 | Sale | EVP, Chief Commercial Officer | 1,605 0.0012% | $231.00 | $370,747 | +9.36% | ||
| 2024-06-25 | Sale | director | 8,500 0.0067% | $240.00 | $2.04M | +9.36% | ||
| 2024-06-24 | Sale | director | 32,450 0.0254% | $220.69 | $7.16M | +17.79% | ||
| 2024-05-29 | Sale | director | 21,700 0.0173% | $148.60 | $3.22M | +72.84% |
Insider Historical Profitability
| Greenstreet Yvonne | Chief Executive Officer | 78880 0.0612% | $249.55 | 0 | 21 | |
| Poulton Jeffrey V. | EVP, Chief Financial Officer | 30644 0.0238% | $249.55 | 0 | 6 | |
| Garg Pushkal | CMO & EVP Dev & Med Affairs | 15705 0.0122% | $249.55 | 0 | 10 | |
| Tanguler Tolga | EVP, Chief Commercial Officer | 13191 0.0102% | $249.55 | 0 | 9 | |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 12881 0.01% | $249.55 | 0 | 4 | |
| SCHULMAN AMY W | director | 8436 0.0065% | $249.55 | 0 | 2 | |
| Franchini Indrani Lall | EVP, CLO & Secretary | 4133 0.0032% | $249.55 | 0 | 4 | |
| PYOTT DAVID E I | director | 136 0.0001% | $249.55 | 1 | 1 | +45.98% |
| Ausiello Dennis A | director | 136 0.0001% | $249.55 | 0 | 10 | |
| SHARP PHILLIP A | director | 0 0% | $249.55 | 2 | 14 | +68.46% |
| Sanofi | 10 percent owner | 10554134 8.1827% | $249.55 | 6 | 0 | +18.68% |
| NOVARTIS AG | 10 percent owner | 4051002 3.1408% | $249.55 | 3 | 1 | <0.0001% |
| Westphal Christoph H | director, 10 percent owner | 300170 0.2327% | $249.55 | 1 | 0 | |
| CHP II LP | 10 percent owner | 232500 0.1803% | $249.55 | 1 | 0 | |
| MARAGANORE JOHN | Chief Executive Officer | 214765 0.1665% | $249.55 | 9 | 42 | +49.04% |
| Abingworth Management LTD | 10 percent owner | 155367 0.1205% | $249.55 | 2 | 6 | +71.97% |
| Berriman John E | director | 155367 0.1205% | $249.55 | 1 | 0 | |
| Greene Barry E | President | 70343 0.0545% | $249.55 | 7 | 18 | +53.61% |
| POLARIS VENTURE MANAGEMENT CO III LLC | 10 percent owner | 30384 0.0236% | $249.55 | 0 | 23 | |
| Vaishnaw Akshay | President | 22774 0.0177% | $249.55 | 0 | 36 | |
| BONNEY MICHAEL W | director | 16029 0.0124% | $249.55 | 2 | 2 | <0.0001% |
| CLARKE JOHN K | director | 8891 0.0069% | $249.55 | 1 | 2 | |
| ATLAS VENTURE FUND V LP | 10 percent owner | 6557 0.0051% | $249.55 | 2 | 2 | 0% |
| KEATING LAURIE | EVP, Chief Legal Officer | 5132 0.004% | $249.55 | 1 | 17 | +78.8% |
| Reid Laurence | SVP, Chief Business Officer | 3905 0.003% | $249.55 | 1 | 7 | +41.4% |
| Barrett Peter | director | 2647 0.0021% | $249.55 | 2 | 9 | 0% |
| PAUL STEVEN M | 2526 0.002% | $249.55 | 1 | 3 | +10.43% | |
| Gros David-Alexandre C | SVP, Chief Business Officer | 1000 0.0008% | $249.55 | 1 | 0 | <0.0001% |
| STARR KEVIN P | director | 0 0% | $249.55 | 0 | 6 | |
| SCHIMMEL PAUL | director | 0 0% | $249.55 | 2 | 15 | +27.77% |
| Fanucci Marsha | director | 0 0% | $249.55 | 1 | 2 | +41.4% |
| VINCENT JAMES L | director | 0 0% | $249.55 | 0 | 5 | |
| Allen Patricia L | VP of Finance and Treasurer | 0 0% | $249.55 | 0 | 2 | |
| Mason Michael | VP, Finance and Treasurer | 0 0% | $249.55 | 0 | 13 |
Institutional Investor Ownership
| Capital World Investors | $1.91B | 10.11 | 12.79M | -20.93% | -$505.94M | 0.32 | |
| The Vanguard Group | $1.79B | 9.48 | 11.99M | +0.42% | +$7.53M | 0.03 | |
| Fidelity Investments | $1.49B | 7.88 | 9.97M | -3.34% | -$51.46M | 0.1 | |
| BlackRock | $1.35B | 7.14 | 9.03M | +5.91% | +$75.31M | 0.03 | |
| Wellington Management Company | $1.08B | 5.7 | 7.21M | -0.07% | -$776,093.85 | 0.18 | |
| Baillie Gifford Co | $989.89M | 5.24 | 6.62M | -4.93% | -$51.34M | 0.77 | |
| Dodge & Cox | $569.63M | 3.01 | 3.81M | +3.73% | +$20.5M | 0.33 | |
| T. Rowe Price | $550.84M | 2.91 | 3.69M | +5.79% | +$30.16M | 0.07 | |
| Capital International Investors | $545.67M | 2.89 | 3.65M | +1.8% | +$9.65M | 0.11 | |
| State Street | $476.95M | 2.52 | 3.19M | +2.33% | +$10.88M | 0.02 | |
| Capital Research Global Investors | $470.02M | 2.49 | 3.14M | +7.33% | +$32.12M | 0.11 | |
| T Rowe Price Investment Management Inc | $429.36M | 2.27 | 2.87M | -16.15% | -$82.67M | 0.26 | |
| Geode Capital Management | $298.72M | 1.58 | 2M | +3.89% | +$11.19M | 0.03 | |
| JPMorgan Chase | $261.27M | 1.38 | 1.75M | -42.04% | -$189.5M | 0.02 | |
| American Century Investments | $205.29M | 1.09 | 1.37M | +231.05% | +$143.28M | 0.13 | |
| Legal & General | $137.67M | 0.73 | 921,195 | -1.05% | -$1.46M | 0.03 | |
| Bellevue Group | $137.24M | 0.73 | 918,284 | +3.72% | +$4.93M | 2.1 | |
| Deep Track Capital Lp | $124.39M | 0.66 | 832,310 | New | +$124.39M | 0.57 | |
| BNY Mellon | $119.33M | 0.63 | 798,445 | -4.62% | -$5.78M | 0.02 | |
| Ubs Asset Management Americas Inc | $113.38M | 0.6 | 758,650 | +2.37% | +$2.63M | 0.04 | |
| Amundi | $108.3M | 0.59 | 746,064 | +4.83% | +$4.99M | 0.05 | |
| Northern Trust | $110.53M | 0.59 | 739,584 | -3.26% | -$3.73M | 0.02 | |
| Morgan Stanley | $100.92M | 0.53 | 675,281 | -16.28% | -$19.62M | 0.01 | |
| Loomis, Sayles & Company | $86.96M | 0.46 | 581,851 | -4.42% | -$4.02M | 0.13 | |
| Squarepoint Ops LLC | $86.75M | 0.46 | 580,441 | +72.84% | +$36.56M | 0.32 | |
| Nuveen | $76.52M | 0.41 | 511,978 | -5.78% | -$4.7M | 0.02 | |
| Deutsche Bank | $75.78M | 0.4 | 507,077 | +9.68% | +$6.69M | 0.03 | |
| Bank of America | $72.47M | 0.38 | 484,893 | +53.33% | +$25.21M | 0.01 | |
| Td Asset Management Inc | $69.1M | 0.37 | 462,348 | -0.8% | -$558,494.65 | 0.06 | |
| Charles Schwab | $66.89M | 0.35 | 447,560 | +2.11% | +$1.38M | 0.02 | |
| Gilder Gagnon Howe & Co. LLC | $60.55M | 0.32 | 405,173 | -30.98% | -$27.18M | 0.77 | |
| Swiss National Bank | $56.18M | 0.3 | 375,900 | -3.81% | -$2.23M | 0.04 | |
| Royal Bank of Canada | $55.96M | 0.3 | 374,424 | +45.15% | +$17.41M | 0.01 | |
| Casdin Capital | $53.5M | 0.28 | 358,000 | +83.59% | +$24.36M | 2.64 | |
| The Manufacturers Life Insurance Company | $50.37M | 0.27 | 337,025 | -1.11% | -$567,162.75 | 0.05 | |
| Royal London Asset Management | $48.85M | 0.26 | 326,869 | +5.84% | +$2.7M | 0.12 | |
| Candriam S C A | $47.36M | 0.25 | 316,898 | +26.57% | +$9.94M | 0.31 | |
| Mitsubishi UFJ Trust and Banking Corporation | $46.61M | 0.25 | 311,852 | -10.68% | -$5.57M | 0.11 | |
| Avoro Capital Advisors Llc | $44.84M | 0.24 | 300,000 | -73% | -$121.22M | 0.54 | |
| Sumitomo Mitsui Trust Holdings | $43.49M | 0.23 | 290,996 | -1.45% | -$640,094.35 | 0.03 | |
| Balyasny Asset Management Llc | $42.99M | 0.23 | 287,627 | New | +$42.99M | 0.12 | |
| Ci Private Wealth Llc | $41.04M | 0.22 | 274,607 | -0.03% | -$13,301.05 | 0.02 | |
| Canada Pension Plan Investment Board | $40.92M | 0.22 | 273,790 | +12.67% | +$4.6M | 0.04 | |
| Goldman Sachs | $38.86M | 0.21 | 260,019 | -10.76% | -$4.69M | 0.01 | |
| HERITAGE ASSET MANAGEMENT INC | $39.6M | 0.2 | 258,248 | -1.76% | -$707,924.59 | 0.2 | |
| Dimensional Fund Advisors | $38.14M | 0.2 | 255,179 | -4.44% | -$1.77M | 0.01 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $36.47M | 0.19 | 244,000 | +3.83% | +$1.35M | 0.95 | |
| Avidity Partners Management Lp | $36.32M | 0.19 | 243,000 | New | +$36.32M | 1.38 | |
| Franklin Templeton Investments | $35.5M | 0.19 | 237,524 | +57.38% | +$12.94M | 0.01 | |
| Schonfeld Group | $35.21M | 0.19 | 235,606 | +11,963.8% | +$34.92M | 0.2 |